Article

Proteomics analysis of Formalin Fixed Paraffin Embedded tissues in the investigation of prostate cancer

Anna Mantsiou, Manousos Makridakis, Konstantinos Fasoulakis, Ioannis Katafigiotis, Constantinos A. Constantinides, Jerome Zoidakis, Maria G. Roubelakis, Antonia Vlahou, and Vasiliki Lygirou

J. Proteome Res., **Just Accepted Manuscript** • DOI: 10.1021/acs.jproteome.9b00587 • Publication Date (Web): 04 Nov 2019

Downloaded from pubs.acs.org on November 5, 2019

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.

1. Introduction

Prostate cancer (PCa) ranks as the second most frequently diagnosed cancer and the fifth leading cause of cancer-related deaths in men's population worldwide, with 1.3 million new cases and 359,000 deaths in 2018 [1]. The major clinical challenge is the inability of current biomarker tests and stratification systems to reliably predict the disease outcome and distinguish the indolent from the highly aggressive PCa tumors [2]. Prostate-Specific Antigen (PSA) is currently the most widely used biomarker test for PCa diagnosis and prognosis. However, it has poor specificity [3] and consequently may lead to unnecessary biopsies and high rates of overdiagnosis and overtreatment. In the last decade, various molecular tests based on genetic markers have been FDA-approved by FDA for PCa diagnosis (SelectMDX, Progenia) and prognosis (OncotypeDx, Prolaris, Decipher), however the lack of cost effectiveness combined with the suboptimal accuracy rates hinder their wide use [4]. Taking these into consideration, there is an emerging clinical need for PCa molecular biomarkers of high specificity and sensitivity that will assess more accurately the disease progression.

Even though main advancements in the characterization of PCa tissue at the DNA/RNA levels have been made, reflected in the current molecular subtyping schemes of the disease [5], large-scale proteomics studies with validated results remain scarce [6]. ~~information at the proteome level is still largely lacking. In addition,~~ The vast majority of ~~the~~ reported proteomics studies on PCa ~~use have applied~~ relatively low resolution proteomic technologies (2DE, 2D-DIGE, RPPA) which are semi-quantitative and provide inadequate proteomic coverage [6–8]. Nevertheless, the number of high resolution proteomics studies on PCa has risen in the last five years uncovering new insights on PCa progression [6,9,10].

Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks represent a valuable source of samples for clinical and translational research, as pathology departments routinely archive them in vast numbers. Tissue fixation routinely takes place in formalin solution (for 24-48 h) enabling the storage of samples in ambient condition for decades [11]. Extracting the molecular profile of FFPE tissues enables prospective and retrospective studies to be performed with adequate statistical power and could greatly facilitate biomarker discovery and validation. In addition, proteomic assessment of FFPE tissue samples can provide precious insights into the molecular mechanisms underlying the disease pathology and hence facilitating the discovery of novel drug targets [6]. Molecular assays for oncological prognosis have been already developed using FFPE tissue samples. Oncotype DX prostate cancer assay, which is a 17-gene RT-PCR assay predicting the aggressiveness of prostate cancer, is such an example [12].

The protein profiling of FFPE tissues is challenging due to the formalin-induced chemical modifications of proteins [13,14]. The induced cross-linking decreases the protein solubility and inhibits its digestion by preventing trypsin or other endopeptidases to reach their cleaving sites [15,16]. In addition, amino acid chemical changes are frequently induced [11,16,17]. As a result, the proteomics output may be compromised. Since the first reported effort ~~to optimize protein extraction from FFPE~~, in 1998, ~~to optimize protein extraction from FFPE~~, using 2% SDS combined with sequential heating steps at 100 °C and 60 °C [18], it was not until 2005 that a shotgun-based workflow for the analysis of FFPE tissue was proposed by Hood et al. [19], using human PCa clinical samples. In this case, protein extraction relied on the use of a commercial kit and heating at 95 °C for 90 min. Upon analyzing the samples by label-based nano-RP-LC-MS/MS- about 1,000 proteins (702 proteins from benign prostatic hyperplasia and 1,153 proteins from prostate carcinoma with 69 proteins being differentially expressed between the two) were reported [19]. Since then, the studies that investigated the global ~~proteome~~ ~~proteomic~~ changes in PCa ~~FFPE samples~~ are scarce, using in some cases low resolution proteomics techniques (2D Gel, MALDI TOF) or extensive fractionation and/or expensive labeling protocols [20–23].

Here we describe a simple and efficient protocol for proteomics analysis of FFPE tissue and demonstrate its efficacy in providing biologically relevant information in the context of PCa through a pilot study, involving the analysis of low versus high risk ~~prostate cancer~~PCa.

2. Materials and Methods

2.1 Tissue samples

~~Archival-FFPE~~ mouse tissue samples, as per availability, [~~{~~kidney and liver; fixed in 10% v/v formalin in water overnight, dehydrated in 70% ethanol, embedded in paraffin and stored at ~~room temperature (RT)~~] were employed for protocol optimization. In some cases, respective frozen tissue samples were also available.

Archival FFPE prostate tissue specimens from 10 patients ~~operated-who had undergone surgery~~ at the Ippokrateio Hospital, Athens, were used in the study, in line to ethics requirements (the study was approved from the Ethics Committee of the Medical School, National and Kapodistrian University of Athens, ~~with~~ protocol number 45/2018). The clinic~~o~~-pathological information associated ~~to-with~~ these specimens is provided in Table S1. FFPE sections (4 μm) from each block were stained with hematoxylin/eosin and examined by the ~~Pathologist~~ ~~pathologist~~ to localize the site of the tumor and evaluate the Gleason grading. Then, tumor and benign regions were collected by microdissection ~~excised~~ from the adjacent unstained sections. The samples used in the current study corresponded to: Gleason Score (GS) 6 (3+3) cancerous tissue (n=4; referred to as 2a-5a) and ~~their~~-benign

~~counterparts adjacent tissues~~ (n=5; referred to as 1b-5b); GS $\geq$ 8 cancerous tissue (n=5; referred to 6a-10a) and their benign ~~adjacent tissues counterparts~~ (n=4; referred to as 6b-9b).

2.2 Protein extraction from FFPE and FF tissue with the optimized protocol

For each FFPE sample, 3 - 4 sections 15 - 20 μ m each were obtained and combined in a 2 ml eppendorf tube for further processing. This included, deparaffinization through three incubations in xylene (first two for 5 min each and the last for 1 min), each one followed by centrifugation for 3 min at 13,000 rpm, at ~~RT room~~ ~~temperature (RT)~~. The sections were then rehydrated through a series of ethanol and distilled water washes (100% ethanol for 2 min, 95% ethanol for 1 min, 70% ethanol for 1 min, distilled water for 1 min), each one followed by centrifugation for 3 min at 13,000 rpm, at RT. Upon rehydration, the tissue pellets were left to air-dry for 30 min at RT. The subsequent steps were common for both FFPE and ~~fresh~~ frozen (FF) samples (without any prior steps for the latter). The samples were resuspended in 200 μ l of FASP buffer (pH $\sim$ 8), containing 100 mM Tris-HCl, 4 % SDS, 100 mM DTE. For homogenization, 0.9 - 2.0 mm stainless steel beads were added to the samples and placed at the bullet blender homogenizer (Bullet Blender Storm BBY24M, Next Advance, USA) in 2 sequential steps: 5 min ~~in-at~~ speed 12 and 3 min ~~in-at~~ speed 10. The homogenates were sonicated for 3 cycles of 5 ~~seconds~~ each using a tip sonicator (36% power used), followed by 1 h of heating at 90 $^{\circ}$ C on a heating block. Then, the extracts were centrifuged for 10 min at 13,000 rpm at RT and the supernatants ($\sim$ 170 μ l) were transferred ~~in-to~~ new 1.5 ml eppendorf tubes and protease inhibitors were added to a final concentration of 3.6% and stored at -80 ~~e~~ $^{\circ}$ C until use.

The extraction buffers that were tested during the optimization process include: PEB buffer (20 mM Tris-HCl, 200 mM DTE, 2% SDS, 20% Glycerol); Urea-Thiourea buffer (7 M Urea, 2 M Thiourea, 4% Chaps, 65 mM DTE, 2% IPG); ~~and FASP buffer (100 mM Tris-HCl, 4 % SDS, 100 mM DTE)~~ (Table 1).

Table 1. Seven combinations of homogenization methods and extraction buffers were used for the FFPE extraction optimization

Homogenization means Extraction buffers	bullet blender	bullet blender, sonication	bullet blender, sonication, heating
PEB (20mM Tris-HCl, 200mM DTE, 2% SDS, 20% Glycerol)	✓		
Urea (7M Urea, 2M Thiourea, 4% Chaps, 65mM DTE, 2% IPG)	✓	✓	✗
FASP (100mM Tris-HCl pH 7.6, SDS 4%, 100mM DTE)	✓	✓	✓

FASP without SDS*

* FASP buffer is added initially without the SDS. SDS is added in final concentration 4% right before the heating step.

2.3 Protein digestion of FFPE prostate clinical tissues

The GeLC-MS method [24] was applied. Samples (protein extract from 3 – 4 sections 15 - 20 μm each, per sample) were concentrated 10 times (using Amicon Ultra Centrifugal Filters, 3 kDa ~~MW~~~~COMW~~ cut-off) with buffer exchange in 50 mM ammonium bicarbonate, pH 8.5. The total amount of the concentrated sample (18 - 20 μl) was then loaded on the polyacrylamide gel and the rest of the protocol was followed exactly as described in [24]. Trypsinization was performed by adding 600 ng of trypsin, for 12 - 16 h, at RT in the dark, in a humidified container. Peptide extraction followed and the peptide solution was lyophilized [24].

2.4 LC-MS/MS analysis and MS data processing

LC-MS/MS analyses were performed on a Dionex Ultimate 3000 UHPLC nano flow system coupled to a Thermo Q Exactive mass spectrometer and an Orbitrap Elite. Prior to the analysis, each sample was reconstituted in 12 μl mobile phase A (0.1% Formic Acid, pH 3.5) and 6 μl loaded on the column. In all cases, raw files were processed with Thermo Proteome Discoverer 1.4 software, utilizing the Sequest search engine and the UniProt human ([downloaded on 16/12/2018 including 20243 reviewed entries](#)) and mouse ([downloaded on 22/11/2017 including 16935 reviewed entries](#)) fasta canonical data-bases (~~downloaded on 16/12/2018 including 20243 reviewed entries~~). The search was performed using carbamidomethylation of cysteine as static and oxidation of methionine as dynamic modifications. Two missed cleavage sites, a precursor mass tolerance of 10 ppm and fragment mass tolerance of 0.05 Da were allowed. For both the human and the mouse samples, the filters used were as follows: Peptide: High Confidence (FDR q value based = 0.01) and Medium Confidence (FDR q value based = 0.05), peptide rank: Maximum rank=1, peptide grouping: enabled, protein grouping: enabled.

2.5 Statistical analysis

The peak area of precursor ions was used to assess the relative abundance of the identified proteins (label free method). Protein abundance in each sample was calculated as the sum of all peptide peak areas from the extracted chromatogram, normalized as follows (ppm): Protein peak area/Total peak area per sample × 10⁶. For the comparison between the cancerous tissues (GS6 and GS≥8; n=9) and the adjacent benign tissues (GS6 and GS≥8; n=9), a threshold of 30% was applied (total number of samples n=18). For the rest of the comparisons, due to the smaller sample size (n=4 or 5 per group) proteins detected in at least 60% of samples in at least one group were considered for quantification and statistical analysis to increase reliability of results. The non-

parametric Mann-Whitney U- test (two tailed, unadjusted) was utilized for defining statistical significance. The test was applied on each of the comparisons using SPSS software (IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp. Released 2013). Fold change for each comparison ~~were~~was calculated as follows: mean value of the case group / mean value of the control group. Proteins with a fold change of ≥ 1.5 (up-regulated) or ≤ 0.67 (down-regulated) were considered as differentially expressed, whereas proteins that are significantly differentially expressed are those that fulfilled both the ~~1.5~~ratio cutoffs and also have a p-value ≤ 0.05 from the Mann-Whitney test.

2.6 Pathway-Bioinformatics analysis

Pathway analysis was performed using the ClueGO plug-in in Cytoscape 3.5.1. Only the significantly deregulated proteins were used as input and they were assigned into two separate lists according to their regulation (up- or down- regulated in cases versus controls). Ontologies were retrieved from the REACTOME pathway database (organism: Homo Sapiens, 2,240 terms with 10,664 available unique genes, updated on March 18, 2019) and only statistically ly significant pathways (*Benjamini-Hochberg* corrected p-value ≤ 0.05 , two-sided hypergeometric test) were taken into account. The rest of the settings were used as default. For simplification, the leading term from each group is presented. The percentage of detected features over all associated genes per group is also displayed under the column “% association” (Tables S2a-S2e).

For the disease association analysis the Open Targets platform was used. The hypergeometric distribution and a scoring process based on evidence from 20 data sources (e.g. Uniprot, GWAS Catalog and PheWAS) was used to allow prioritization of targets based on the strength of their association with a disease. The scoring process generate a relevance p value representing the probability that the given list of targets are specific to a disease. Only urological cancers with a relevance p-value ≤ 0.05 were selected.

3. Results

3.1 Establishment of optimized protocol

Initial experiments were performed to establish an efficient and simple protocol for protein extraction from FFPE tissue. The tested methods were based on earlier studies [20–23] and experience in our laboratory from the analysis of tissue material of limited amount [25,26], taking also into account compatibility with mass spectrometry. The methods ~~specifically~~included the use of four different protein extraction buffers in combination to different homogenization means (Table 1 and Figures S1a-S1b). In all cases, 3 sections of ~~archival~~ liver and kidney FFPE tissues (as per availability) were employed, to simulate realistic scenarios of clinical available starting material ~~scenarios from clinical samples~~. The yield and quality of extracted proteins were

initially evaluated by SDS-PAGE analysis (Figure S1a). Based on this, following which, application of Tris-HCl, SDS and DTE (FASP buffer) in combination with bead homogenization, sonication and boiling, was selected for further detailed evaluation by GeLC-MS analysis. An overview of the applied workflow for the optimization of the protein extraction from FFPE tissues is illustrated in Figure 1.

Figure 1. Overview of the applied workflow for the FFPE protein extraction optimization. ~~Eight~~Seven protocols were tested and evaluated for the protein extraction efficiency-efficacy from FFPE tissues.

For further evaluation of the efficiency of the protocol, a side by side comparison of FFPE tissue with respective fresh frozen (FF) mouse kidney tissue material was also performed. Specifically, 4 FFPE replicates and 2 FF replicates using different sections of the same sample for each type were used. In our analysis, we used reasonably stringent criteria (detailed in materials-Materials and methodsMethods) in order to eliminate most of the false positive protein identifications (IDs). ~~b~~Based on these criteria, which 14802,056 unique proteins ~~derived from a list of 10661-identified peptides~~ were in total detected. The full list of proteins is reported in

Table S3a. Among the proteins that were identified, 853 identifications were based on ≥ 2 peptides and 627 were single peptide identifications. The selected protocol yielded a similar number of protein identifications-IDs from both FF and FFPE tissue (FF IDs: 1,736-1214 in 2 samples, FFPE IDs: 1,437-1249 in 4 samples) (Table S3a) and it was also found to provide reproducible results both within and between the two different preservation methods sample types: an overlap rate of about 63–7251 - 62% among the total IDs of the FFPE samples (n=4 replicates) and a 93-9680 - 86% among the total IDs in FF samples (n=2 replicates) were noted. In addition, for the common proteins identified in all samples of a group (FF: 1,216, FFPE: 530), a high overlap between the FF and FFPE samples was noted with 610-502 proteins detected in both types of samples (Figure 2A and Table S3b). Importantly, a strong positive correlation in the relative abundances of the common proteins detected in all the FFPE and FF samples was noted (Spearman's rank-order correlation was also positive and statistically significant ($r_s = 0.8460.819$, $p < 0.01$, 2-tailed) (Figure 2B and Table S3b). Proteins identified from FF and FFPE samples were also mapped using the Gene Ontology term mapper (<https://go.princeton.edu/cgi-bin/GOTermMapper>) for cellular compartments. The generic terms Cytoplasm, Membrane and Nucleus were used for simplification. As shown in Figure 3, the detected proteins are distributed between the three main cellular compartments in a very similar way for the FFPE and FF samples (Figure 3). The same applies when protein segregation by molecular function was investigated as shown in Figure S2.

A

B

Figure 2. Reproducibility and effectiveness of the optimized proteomics protocol shown in a side by side comparison of FFPE with respective FF tissues. A. The Venn diagram shows that there is significant overlap (n=610-502 common identifications) among the proteins identified in all samples per group (n=4 for FFPE; n=2 for FF)-FFPE and FF samples. B. A strong positive correlation is noted between the relative abundances of the 610-502 common proteins identified in all FF and FFPE samples (Spearman's rho=0.8460.819).

Figure 3. Distribution of the total number of proteins identified in FF and FFPE tissues among the three main cellular compartments. The percentages have been calculated against the total component hits.

3.2 Application in analysis of FFPE PCa tissue

231 The optimized protocol was then implemented in a preliminary study aiming to analyze archived clinical
232 prostate FFPE samples representing different risk categories. Specifically, the study ~~specifically~~ involved the
233 analysis of 18 FFPE PCa tissue samples, representing GS=6, GS≥8 and respective adjacent benign regions.
234 Analysis by GeLC-MS/MS, in this case, provided a mean of approximately 700 proteins per sample, apparently a
235 lower number compared to the ~~obtained~~ protein identifications obtained during the protocol optimization in
236 mouse FFPE tissues. This result is likely attributed to differences in fixation and storage conditions (Lists the
237 lists of detected proteins ~~is-are~~ provided in Table S4a).

238 Five different comparisons were performed: GS≥8 cancer versus GS=6 cancer tissue, GS≥8 adjacent benign
239 versus GS=6 adjacent benign tissue, GS=6 cancer versus GS=6 adjacent benign tissue, GS≥8 cancer versus GS≥8
240 adjacent benign tissue, and all analyzed cancer samples (GS=6 and GS≥8) ~~cancer tissues~~ versus all analyzed
241 benign samples (GS=6 and GS≥8 adjacent benign tissues). To graphically represent the proteomic changes
242 between the different groups of ~~tissues~~ samples, a volcano plot [$-\log_{10}(\text{P value})$ vs. $\log_2(\text{Fold-change})$] was
243 constructed for each one of the comparisons ~~groups~~ (Figure 4) and the number of differentially expressed
244 proteins per comparison is summarized in Table S4g. As ~~it is~~ shown in all plots, the population of the proteins
245 above and below the cut-offs is symmetrically distributed. Indicative differentially expressed proteins ~~changes~~
246 are shown in ~~tables~~ Tables 2 and 3, and include ~~ing~~ proteins involved in ~~of the~~ ECM organization, chromosomal
247 and cytoskeletal proteins, proteins ~~that~~ implicated in translation and in ~~the processes of~~ endocytosis ~~and~~
248 /exocytosis. These observations which are ~~also~~ consistent with ~~already~~ published data as shown in Tables (Table
249 2, and Table 3).

250

Figure 4. Volcano plot illustrates significantly differentially abundant proteins in the comparisons. A. All cancers (GS=6, GS≥8) cancer vs. all benign (GS=6, GS≥8 adjacent benign), B. GS≥8 cancer vs. GS=6 cancer, C. GS=6 cancer vs. GS=6 benign, D. GS≥8 cancer vs. GS≥8 benign and E. GS≥8 benign vs. GS=6 benign. The $-\log_{10}$ (Benjamini-Hochberg corrected p -value) is plotted against the $\log_2$ (fold change). The non-axial vertical lines denote ± 1.5 -fold change; Points to the left of the left-most non-axial vertical line denote protein fold changes less than -1.5, while points to the right of the right-most non-axial vertical line denote protein fold changes greater than 1.5. The non-axial horizontal line denotes P -p-value = 0.05 (Mann-Whitney); which is our significance threshold prior to logarithmic transformation; P and points above the non-axial horizontal line represent proteins with significant ly differences differentia abundances (Mann-Whitney $p < 0.05$).

Table 2. Top 20 differentially expressed proteins showing the most significant abundance changes between GS=6 cancer and GS=6 adjacent benign counterparts, based on a ranking combining the protein abundance ratio and the p -value from the Mann-Whitney test ($\log_2(\text{Ratio}) * -\log_{10}(p\text{-value})$). Literature information for proteins that have been previously studied-reported in association to PCa are is also given.

Accession ID	Description	Gene Symbol	Ratio GS6 cancer Vs GS6 benign	M-W p-value GS6 cancer Vs GS6 benign	Reference *
Up-regulated in cancer					
P16104	Histone H2AX	H2AFX	100.049	0.011	
P63241	Eukaryotic translation initiation factor 5A-1	EIF5A	43.448	0.011	
P13647	Keratin, type II cytoskeletal 5 *	KRT5	25.641	0.011	[27,28]
P02511	Alpha-crystallin B chain *	CRYAB	20.504	0.021	[29,30]
P61158	Actin-related protein 3	ACTR3	20.334	0.046	
P54819	Adenylate kinase 2, mitochondrial	AK2	18.090	0.021	
O00148	ATP-dependent RNA helicase DDX39A	DDX39A	9.721	0.011	
P14550	Alcohol dehydrogenase [NADP(+)]	AKR1A1	7.290	0.021	
Q96E39	RNA binding motif protein, X-linked-like-1	RBMXL1	6.436	0.013	
P32969	60S ribosomal protein L9	RPL9	6.330	0.021	
Up-regulated in benign					
Q15149	Plectin *	PLEC	0.266	0.014	[31]
P01008	Antithrombin-III	SERPINC1	0.251	0.014	[32]
P61019	Ras-related protein Rab-2A	RAB2A	0.222	0.014	
P08133	Annexin A6	ANXA6	0.183	0.014	
P84243	Histone H3.3	H3F3A	0.180	0.014	
P15090	Fatty acid-binding protein, adipocyte *	FABP4	0.166	0.014	[33,34]
Q9Y6C2	EMILIN-1	EMILIN1	0.162	0.027	
P18206	Vinculin	VCL	0.155	0.014	[35,36]

1						
2						
3						
4		P98160	Heparan sulfate proteoglycan core protein	HSPG2	0.136	0.05 [37,38]
5			^{1*}			
6		P59665	Neutrophil defensin 1	DEFA1	0.069	0.014 [39]
7	267					
8	268	¹ The asterisk indicates an opposite expression trend compare to the finding in the current study or contradictory literature data				
9	269	^{2*} Literature information have has been retrieved from studies comparing PCa versus BPH and/or benign and/or normal in tissues or				
10	270	models by applying different methodological approaches (IHC, Western blot, mass spectrometry).				
11	271					
12	272					
13	273					

274 **Table 3.** Top 20 differentially expressed proteins showing the most significant abundance changes between
275 GS≥8 cancer and GS≥8 adjacent benign counterparts, based on a ranking combining the protein abundance ratio
276 and the p-value from the Mann-Whitney test (log2(Ratio) * -log10(p-value)). Literature information for proteins
277 that have been previously reported in association to PCa studied are is also given.
278

Accession ID	Description	Gene Symbol	Ratio GS≥8 cancer Vs GS≥8 benign	M-W p-value GS≥8 cancer Vs GS≥8 benign	Reference [*]
Up-regulated in cancer					
Q13162	Peroxiredoxin-4	PRDX4	11.000	0.013	[6,40,41]
P08779	Keratin, type I cytoskeletal 16	KRT16	8.578	0.014	[42]
P02533	Keratin, type I cytoskeletal 14 [*]	KRT14	5.395	0.014	[43]
P21397	Amine oxidase [flavin-containing] A	MAOA	5.273	0.049	[44]
P05141	ADP/ATP translocase 2	SLC25A5	4.672	0.046	
P54819	Adenylate kinase 2, mitochondrial	AK2	4.637	0.05	
P31040	Succinate dehydrogenase flavoprotein	SDHA	4.204	0.049	[45]
Q9NVD7	Alpha-parvin	PARVA	3.708	0.049	[46]
Q9UHG3	Prenylcysteine oxidase 1	PCYOX1	3.662	0.049	
P13639	Elongation factor 2	EEF2	2.774	0.014	[47]
Up-regulated in benign					
Q6PCB0	von Willebrand factor A domain-protein 1	VWA1	0.489	0.014	
P60660	Myosin light polypeptide 6	MYL6	0.488	0.027	
P15088	Mast cell carboxypeptidase A	CPA3	0.355	0.05	
P00387	NADH-cytochrome b5 reductase 3	CYB5R3	0.287	0.05	
Q08257	Quinone oxidoreductase	CRYZ	0.275	0.027	[48,49]
O75368	SH3 domain-binding glutamic acid-rich-like	SH3BGRL	0.246	0.014	
O14558	Heat shock protein beta-6	HSPB6	0.223	0.05	
Q08380	Galectin-3-binding protein [*]	LGALS3BP	0.203	0.014	[50]
P08648	Integrin alpha-5 [*]	ITGA5	0.121	0.014	[51]

P30046	D-dopachrome decarboxylase	DDT	0.081	0.021
--------	----------------------------	-----	-------	-------

¹The asterisk indicates an opposite expression trend compare to the finding in the current study or contradictory literature data
^{2*} Literature information ~~have~~ has been retrieved from studies comparing PCa versus BPH and/or benign and/or normal in tissues or models by applying different methodological approaches (IHC, Western blot, mass spectrometry).

Significantly differentially expressed proteins were subjected to pathway classification, using the Reactome database, to investigate the deregulated molecular pathways (Figure 5 and Tables S2a-S2e). To simplify the analysis output, only the leading terms of each pathway are presented. Proteins significantly deregulated between the more aggressive PCa GS $\geq$ 8 and PCa ~~of~~ GS=6 ~~were~~ segregated into pathways involved in metabolism and kinase signalling extracellular matrix interactions and organisation, protein phosphorylation and gluconeogenesis, in line to existing literature [52,53] on aggressive forms of prostate cancer (Figure 5A). On the other hand, when comparing the cancerous tissues with the adjacent benign ~~counterpartstissues~~, in all cases, the pathways that were enriched in the former, represented translation, peptide synthesis and protein metabolism (Figure 5B, C, D), as expected [54,55].

A

GS>8 cancer vs. GS6 cancer

B

GS6 cancer vs. GS6 benign

C

GS>8 cancer vs. GS>8 benign

D

GS6 and GS>8 cancer vs. GS6 and GS>8 benign

Figure 5. Enrichment pathway analysis of the proteins with significant differences between the different comparing groups. Only the leading terms of each pathway group are presented, based on significance which is illustrated from the size of the bars. Green color illustrates the pathways that contain more than 50% of genes which found up-regulated in case (always the first group in each graph title) versus control (always the second group in graph title). While the pathways containing more than 50% of genes up-regulated in control versus case, are illustrated with red color. A. GS $\geq$ 8 cancer vs. GS=6 cancer, B. GS=6 cancer vs. GS=6 benign, C. GS $\geq$ 8 cancer vs. GS $\geq$ 8 benign and D. all cancersGS6 and GS>8 cancer vs. allGS6 and GS>8 benigns.

To further evaluate our findings, the differentially expressed proteins from the comparison of cancer (GS=6 and GS $\geq$ 8) versus benign (GS=6 and GS $\geq$ 8) were analysed on the Open Targets Platform [56] which combines evidence from various data sources, allowing target identification, and prioritisation, as well as and association with diseases. The analysis demonstrated that out of the 180 significantly differentially expressed proteins found in this comparison, 106 have been significantly (stat. test p-value $\leq$ 0.05) associated with prostate cancer including prostate carcinoma and adenocarcinoma, and metastatic prostate cancer. Furthermore, out of these 106 PCa associations, 86 were also associated with other urological cancers (bladder, kidney and testicular carcinoma) while 19 more proteins were found to be implicated only in other urological cancers and not in prostate malignancies. The results of the disease association analysis are shown in detail in Table S5. The high percentage of associations with PCa in this analysis supports the relevance of our proteomics results in the context of PCa and the efficiency of the optimized protein extraction protocol used for FFPE samples.

4. Discussion

There are relatively few published proteomic analyses of FFPE prostate tissues [6] (summarized in Table S6a). The majority of the studies focused on methodological approaches of extracting proteins from FFPE blocks using either low resolution proteomics techniques or applying LC-MS/MS with extensive fractionation and expensive labeling protocols [19–21,57–59]. SpecificallyCharacteristically, there are three proteomic reports using an SDS-based extraction protocol combined with heating and LC-MS/MS as proteomic platform to elucidate protein differences between FFPE PCa tissues and the adjacent counterparts. Using a case-control study design, Dunne et al. [23] used LC-MS/MS to identify protein changes between 16 primary PCa cases of GS 6-10 and 16 adjacent benign areas; in this study, resulting in 242 protein IDs, in total. In a similar report, Iglesias et al., using an SDS-based extraction buffer and LC-MS/MS with extensive fractionation of the samples, were able to identify 649 differentially expressed proteins between 28 PCa samples (GS 6-9) and 8 adjacent nonmalignant tissues [22]. Moreover, Turiak et al. used tissue microarrays TMAs from FFPE blocks, including 10 cases of PCa and 2 healthy prostate tissues, resulting in the identification of 500 proteins on average, from each sample, using label-free quantitative LC-MS/MS analysis, also showing high grade of technical reproducibility

[8]. A cumulative table of the proteomic studies using FFPE tissues in the context of PCa and their main characteristics is presented (Table S6a). A comparison of the differentially expressed proteins in the current study with the significantly altered proteins reported by Iglesias-Gato et al. [22] (PCa GS 6-9 vs adjacent benign) is presented in Table S6b, as it is the only study performing a similar comparison to ours (PCa GS=6 and GS≥8 vs adjacent benign). In total, 107 proteins were differentially expressed in both studies, out of which, 83 follow the same expression trend in cancer compared to adjacent benign.

Our overall goal for this study was to investigate whether differential protein expression analysis from archival FFPE prostate cancer tissues with a simple, fast and label-free protocol using high resolution proteomics is feasible. Following an initial method development phase evaluating ~~eight~~seven different protocols, compiling information from the existing literature [19–21,57–59], use of an extraction buffer including 100mM Tris-HCl, 4 % SDS, 100mM DTE in combination with bead homogenization, sonication and boiling was selected.

This optimized buffer contained 4% SDS, higher than the ~~least~~-recommended concentration for such analyses (2% SDS; [60]) and reported to effectively solubilize fixed proteins from FFPE tissues due to its dual denaturing and detergent actions [15,61].- Increase in protein extraction efficacy was noted when this buffer was combined with at least 60 °C heating. This is in line to several studies supporting a direct correlation between the protein yield from FFPE specimens and applied temperature [18,59,62,63]. Specifically, it has been suggested that heating may lead to protein unfolding, removal of covalent cross-links and hydrolysis of methylene bridges [62–64] with optimal results obtained at 65°C [59]. Besides the temperature, the effect of pH on the protein extraction efficacy has also been reported [16,59,62]. Several studies agree on the general finding that incubation of FFPE sections in buffers with basic pH (~8.0) give higher yield, while extraction in acidic or close to neutral pH (~7-7.5), generally provide a lower protein amount [16,59,62]. Our protocol, which includes an extraction buffer with pH (~~~8.0~~), is also in line with these reports.

Several studies aim ~~Targeting~~ to evaluate if the FFPE tissues ~~form offer~~ a reliable alternative to ~~fresh frozen~~FF samples, ~~several studies have been performed by~~ comparing the protein profiles between the two types of samples [59,60,65–67]. Overlaps in protein identifications between the FFPE and FF samples are in general high, ~~with rates~~-ranging between 75 and 92% [59,60,65–67]. Higher variability is noted in the number of identified proteins per study: In some cases, clear superiority of the FF over the FFPE samples [15,65,68,69] was observed, while others reported comparable results [70,71]. In one case, a higher number of protein identifications (by about 30%) in FFPE samples compared to FF tissue was ~~observed~~reported [72]. These results may largely reflect differences among individual protocols but also the potential impact of the fixation protocols and storage conditions, which ~~cannot generally not~~ be controlled, generally, when analyzing archival tissues. In our analysis, the described protocol resulted in the detection of about ~~1000~~950 proteins on average, in FFPE samples, which

is still lower to the respective FF output (about 1,500 proteins on average, per sample). However, the two types of samples had with high overlap rates in their protein IDs (95% of the FFPE and 41% of the FF protein IDs were common) and significant correlation ($r_s = 0.8460.819$, $p < 0.01$) in the relative protein abundances, when the FFPE tissues were compared with the respective FF tissues. Additionally, GO analysis supported showed that similar percentages of membrane proteins isolated from FFPE and FF tissues were detected. This further suggests supports the efficacy of the applied protocol and its potential usefulness in the study of tumor-tumor-relevant signaling pathways.

In the context of this study, the optimized protocol was implemented in a proof of concept analysis of 18 FFPE PCa tissue samples, representing GS=6, GS≥8 and respective adjacent benign regions. Of the detected proteins, the vast number-majority of the high abundance identifications were cytoskeletal and ribosomal proteins, as well as nuclear histones, as expected [73]. Comparisons of the different groups highlighted many expected protein changes in cancer, based on the current literature. These include as examples, Peroxiredoxins 3 and 4 (PRDX3 and PRDX4), Methylcrotonoyl - CoA carboxylase beta chain (MCCC2), Vinculin (VCL) and Prohibitin (PHB), previously validated in more than one study as deregulated in PCa compared to adjacent benign tissues, similarly found to differentially expressed and with same trends of expression in the studied cancer cases versus adjacent controls [6]. Interestingly, in the comparisons GS≥8 versus GS=6 cancerous tissues, GS≥8 adjacent benign tissues versus GS=6 adjacent benign tissues, GS≥8 cancerous tissues versus GS≥8 adjacent benign tissues, albeit non-statistically significant in the two latter cases, PSA was found down-regulated by at least 0.2-fold, in GS≥8 groups, in the aforementioned comparisons. This finding is also supported by a targeted proteomic study utilizing Selected Reaction Monitoring (SRM) in tissue samples where it was shown that PSA levels decreased in localized PCa (GS=7) and in metastatic PCa tumors when compared to benign tissues [74]. Multiple additional proteins (in total 25 out 63 [75]) earlier reported to differ in cancer versus benign [75] were also detected as differentially expressed in our respective comparison. Out of these 25 proteins, 21 exhibit the same expression trend in our data and previous reports [75]; these include Keratin, type II cytoskeletal 8, Peroxiredoxin-4, Growth/differentiation factor 15, Eukaryotic initiation factor 4A-III, Metalloproteinase inhibitor 1, that and others were specifically found also to agree in the expression trend in similar comparison groups as in our study (Table S6S7).

The relevance of the proteomics output result observed at the individual protein level was also observed when investigating biological processes reflected by the observed protein changes, with Neutrophil degranulation [76], Rho GTPase signaling [77], mRNA metabolic processes [54], glycolysis/glyconeogenesis pathway [54] and mitogen-activated protein kinases (MAPK)-signaling [78] predicted to be changing in GS≥8 vs GS=6 as earlier reported. Similarly, significantly deregulated proteins in cancer versus benign segregated into

1
2
3 393 pathways relevant to cancer molecular pathology such as ~~or and~~ protein translation [55], ECM organization [79]
4 394 and mRNA splicing [80]. ~~in cancer versus benign, as earlier reported.~~ Collectively, these results support the
5
6 395 reliability of the established procedure and further applicability to extract valuable information at the protein
7
8 396 level, forming the basis for its further use in large scale PCa –related molecular studies.
9
10 397 Along the same lines, since androgen receptor (AR) signaling is known to play an important role in the
11 398 pathogenesis of PCa [81,82], we also investigated the differentially expressed proteins in our comparisons in
12 399 regards to their association with the AR pathway (based on PathCards [83,84]). Interestingly, AR-linked proteins
13 400 were included, namely, Filamin-A (GS≥8 cancer vs. GS=6 cancer; GS=6 cancer vs. GS=6 benign); GTP-binding
14 401 nuclear protein Ran A (GS≥8 cancer vs. GS=6 cancer; GS=6 cancer vs. GS=6 benign); Destrin (GS≥8 cancer vs.
15 402 GS=6 cancer); Caveolin-1 (GS≥8 cancer vs. GS=6 cancer); Prostate-specific antigen (GS≥8 cancer vs. GS=6 cancer);
16 403 and Receptor of activated protein C kinase 1 (GS=6, GS≥8 cancer vs. GS=6, GS≥8 benign; GS=6 cancer vs. GS=6
17 404 benign). Additional proteins from our datasets, that are linked to the pathway but did not pass our criteria for
18 405 differential expression, include Catenin beta-1; Cell division control protein 42 homolog; Calreticulin;
19 406 Protein/nucleic acid deglycase DJ-1; and Peroxiredoxin-1. These findings further enhance the validity of our
20 407 proteomic results but the analysis of a bigger cohort is needed to draw solid conclusions with respect to the
21 408 biological relevance of these results.
22
23 409 It should be noted that the analyzed sections contain stroma elements and no specific enrichment for
24 410 epithelial components was made in the context of this pilot study. Upon comparison with an earlier proteomic
25 411 analysis of normal and diseased stroma isolated from PCa patients [85], an overlap of 30-40 proteins from the
26 412 earlier described differentially expressed proteins with the total protein identification from each of the
27 413 comparisons in our study may be seen, which might reflect the stroma influence in the results.
28
29
30
31
32
33
34
35
36
37
38
39

40 415 **5. Conclusions**

41
42 416 From a methodological standpoint, the protocol presented here combining different aspects of earlier
43 417 described protocols, is simple and fast, applicable to limited amounts of clinical samples (as expected in the
44 418 cases of small pieces of tissue biopsies), yielding comprehensive datasets that permit further investigation and
45 419 knowledge extraction. With no doubt, due to the expected variability associated with differences in fixation and
46 420 storage conditions, future studies should include the analysis of large numbers of well characterized FFPE
47 421 samples with advanced LC/MS-MS approaches, targeting to reliably reveal protein changes associated with PCa
48 422 phenotypes and progression.
49
50
51
52
53
54 423

55 424 SUPPORTING INFORMATION:

Figure S1. Protocol optimization for protein extraction from the FFPE blocks. Impact of buffer and homogenization means on extracted proteins as defined by SDS-PAGE.

Figure S2. GO Molecular functional comparative analysis between FF and FFPE tissues. The genes corresponding to the total number of proteins ~~that totally~~ identified in FF and FFPE samples were mapped using the Gene Ontology term mapper (<https://go.princeton.edu/cgi-bin/GOTermMapper>) for molecular functions. ~~Importantly~~As shown, the genes are distributed between the molecular functions in a very similar way in the FFPE and the FF samples.

Table S1. Clinical characteristics of the patient cohort. This study comprised 10 patients with histologically confirmed PCa in radical prostatectomy. Five patients had Gleason score 6 (3+3) and five patients has Gleason scores 8 (4+4) and 9 (4+5 or 5+4). Here, specimens of the primary tumors ~~that were investigated were~~ stored as FFPE blocks ~~were analyzed~~.

Table S2. ~~Enrichment analysis for Reactome pathways for the comparisons (a) GS $\geq$ 8 cancer vs. GS $\geq$ 8 benign, (b) GS=6 cancer vs. GS=6 benign, (c) Cancer (GS=6, GS $\geq$ 8) vs. Benign (GS=6, GS $\geq$ 8), (d) GS $\geq$ 8 cancer vs. GS=6 cancer, (e) GS $\geq$ 8 benign vs. GS=6 benign. Only the significantly differentially expressed proteins were used as input and only the leading terms based on significance are presented.~~Enrichment analysis for Reactome pathways for the comparisons ~~GS $\geq$ 8 cancer vs. GS $\geq$ 8 benign (Table S2a), GS=6 cancer vs. GS=6 benign (Table S2b), Cancer (GS=6,GS $\geq$ 8) vs. Benign (GS=6,GS $\geq$ 8) (Table S2c), GS $\geq$ 8 cancer vs. GS=6 cancer (Table S2d), GS $\geq$ 8 benign vs. GS=6 benign (Table S2e). Only the significantly differentially expressed proteins were input and only the leading terms based on significance are presented.~~

Table S3. ~~All proteins detected per sample as well as a Spearman's correlation analysis between FFPE and FF mouse kidney tissues are shown (a) All proteins detected per sample are listed below. The raw area values are given. Zeros indicate the missing values, the proteins that have not been detected (b) Correlation analysis between FFPE and FF mouse kidney tissues. The numbers given refer to proteins which were present in ALL the replicates per group. Spearman's correlation values have been calculated per wise for the samples individually but also for the average values.~~All proteins detected per sample as well as a Spearman's correlation analysis between FFPE and FF mouse kidney tissues are shown.

Table S4. ~~a) All proteins detected per sample in the clinical FFPE tissues are shown. Differential expression analysis for the comparisons (b) GS $\geq$ 8 cancer vs. GS=6 cancer, (c) GS $\geq$ 8 benign vs. GS=6 benign, (d) GS=6 cancer vs. GS=6 benign, (e) GS $\geq$ 8 cancer vs. GS $\geq$ 8 benign, (f) Cancer (GS=6, GS $\geq$ 8) vs. Benign (GS=6, GS $\geq$ 8) are given indicating the proteins below the threshold for significance (p-value $\leq$ 0.05) and with an abundance ratio $\geq$ 1.5 with green color and proteins with p-value $\leq$ 0.05 and abundance ratio $\leq$ 0.67 with red color. (g) Summary of the significantly deregulated proteins per comparison.~~All proteins detected per sample in the clinical FFPE tissues

are shown. Differential expression analysis for all the comparison groups are given as well indicating the proteins below the threshold for significance ($p\text{-val} \leq 0.05$) and with an abundance ratio ≥ 1.5 with green color and proteins with $p\text{-val} \leq 0.05$ and abundance ratio ≤ 0.67 with red color.

Table S5. Results from the disease association of the significantly differentially expressed proteins in the comparison ~~GS $\geq$ 8, GS=6 of all~~ cancers (case) ~~vs GS $\geq$ 8, GS=6 all~~ adjacent benign (control) using the Open Targets Platform.

Table S6 (a) An overview of proteomics studies performed in FFPE tissues in the context of prostate cancer. (b) Comparison of the findings in the current study with the study by Iglesias-Gato et al. 2015 (PMID: 26651926) in the same comparison between Tumor (n=28) and adjacent non-malignant prostate tissue (n=8). Multiple proteins (in total 107 out of 649), earlier reported to differ in cancer versus benign, were also detected as differentially expressed in our respective comparison GS $\geq$ 8, GS=6 cancer (case) vs adjacent benign GS $\geq$ 8, GS=6 (control). Proteins that exhibit the same expression trend are highlighted.

Table S76. Comparison of the findings in the current study with the literature (review, PMID: 29939814). Multiple proteins (in total 25 out of 63), earlier reported to differ in cancer versus benign, were also detected as differentially expressed in our respective comparison GS $\geq$ 8, GS=6 cancer (case) vs adjacent benign GS $\geq$ 8, GS=6 (control). Proteins that exhibit the same expression trend in similar comparisons in our data and previous reports are highlighted. Comparison of the findings in the current study with the literature (Review 2017). Multiple proteins (in total 25 out 63) earlier reported to differ in cancer versus benign were also detected as differentially expressed in our respective comparison GS8, GS6 cancer(case) Vs adjacent benignGS $\geq$ 8, GS=6 (control); Proteins that exhibit the same expression trend and in similar comparison groups in our data and previous reports are highlighted.

Funding

This work was supported by Translational Research Network for Prostate Cancer (721746 - TransPot - H2020 - MSCA - ITN - 2016) 721746.

Conflict of interest

All authors declare no competing financial interest.

References

- 1
2
3 488 [1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN
4 489 estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*
5 490 2018;68:394–424. doi:10.3322/caac.21492.
- 7 491 [2] Romero Otero J, Garcia Gomez B, Campos Juanatey F, Touijer KA. Prostate cancer biomarkers: an
8 492 update. *Urol Oncol* 2014;32:252–260. doi:10.1016/j.urolonc.2013.09.017.
- 10 493 [3] Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer
11 494 biomarkers. *Sci Transl Med* 2012;4:127rv3. doi:10.1126/scitranslmed.3003180.
- 13 495 [4] Alford AV, Brito JM, Yadav KK, Yadav SS, Tewari AK, Renzulli J. The use of biomarkers in prostate cancer
14 496 screening and treatment. *Rev Urol* 2017;19:221–234. doi:10.3909/riu0772.
- 16 497 [5] Frank S, Nelson P, Vasioukhin V. Recent advances in prostate cancer research: large-scale genomic
17 498 analyses reveal novel driver mutations and DNA repair defects. [version 1; peer review: 2 approved].
18 499 *F1000Res* 2018;7. doi:10.12688/f1000research.14499.1.
- 20 500 [6] Mantsiou A, Vlahou A, Zoidakis J. Tissue proteomics studies in the investigation of prostate cancer.
21 501 *Expert Rev Proteomics* 2018;15:593–611. doi:10.1080/14789450.2018.1491796.
- 23 502 [7] Müller A-K, Föll M, Heckelmann B, Kiefer S, Werner M, Schilling O, et al. Proteomic characterization of
24 503 prostate cancer to distinguish nonmetastasizing and metastasizing primary tumors and lymph node
25 504 metastases. *Neoplasia* 2018;20:140–151. doi:10.1016/j.neo.2017.10.009.
- 27 505 [8] Turiák L, Ozohanics O, Tóth G, Ács A, Révész Á, Vékey K, et al. High sensitivity proteomics of prostate
28 506 cancer tissue microarrays to discriminate between healthy and cancerous tissue. *J Proteomics*
29 507 2019;197:82–91. doi:10.1016/j.jprot.2018.11.009.
- 31 508 [9] Sinha A, Huang V, Livingstone J, Wang J, Fox NS, Kurganovs N, et al. The proteogenomic landscape of
32 509 curable prostate cancer. *Cancer Cell* 2019;35:414–427.e6. doi:10.1016/j.ccell.2019.02.005.
- 34 510 [10] Latonen L, Afyounian E, Jylhä A, Nättinen J, Aapola U, Annala M, et al. Integrative proteomics in
35 511 prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease
36 512 progression. *Nat Commun* 2018;9:1176. doi:10.1038/s41467-018-03573-6.
- 38 513 [11] Nirmalan NJ, Harnden P, Selby PJ, Banks RE. Mining the archival formalin-fixed paraffin-embedded
39 514 tissue proteome: opportunities and challenges. *Mol Biosyst* 2008;4:712–720. doi:10.1039/b800098k.
- 41 515 [12] Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, et al. Analytical
42 516 validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate
43 517 needle biopsies. *BMC Genomics* 2013;14:690. doi:10.1186/1471-2164-14-690.
- 45 518 [13] Mason JT, O'Leary TJ. Effects of formaldehyde fixation on protein secondary structure: a calorimetric
46 519 and infrared spectroscopic investigation. *J Histochem Cytochem* 1991;39:225–229.
47 520 doi:10.1177/39.2.1987266.
- 49 521 [14] Matsuda KM, Chung J-Y, Hewitt SM. Histo-proteomic profiling of formalin-fixed, paraffin-embedded
50 522 tissue. *Expert Rev Proteomics* 2010;7:227–237. doi:10.1586/epr.09.106.
- 51
52
53
54
55
56
57
58
59
60

1
2
3 523 [15] Jiang X, Jiang X, Feng S, Tian R, Ye M, Zou H. Development of efficient protein extraction methods for
4 524 shotgun proteome analysis of formalin-fixed tissues. *J Proteome Res* 2007;6:1038–1047.
5 525 doi:10.1021/pr0605318.
6
7 526 [16] Azimzadeh O, Barjaktarovic Z, Aubele M, Calzada-Wack J, Sarioglu H, Atkinson MJ, et al. Formalin-fixed
8 527 paraffin-embedded (FFPE) proteome analysis using gel-free and gel-based proteomics. *J Proteome Res*
9 528 2010;9:4710–4720. doi:10.1021/pr1004168.
10
11 529 [17] Magdeldin S, Yamamoto T. Toward deciphering proteomes of formalin-fixed paraffin-embedded (FFPE)
12 530 tissues. *Proteomics* 2012;12:1045–1058. doi:10.1002/pmic.201100550.
13
14 531 [18] Ikeda K, Monden T, Kanoh T, Tsujie M, Izawa H, Haba A, et al. Extraction and Analysis of Diagnostically
15 532 Useful Proteins from Formalin-fixed, Paraffin-embedded Tissue Sections. *Journal of Histochemistry &*
16 533 *Cytochemistry* 1998;46:397–403. doi:10.1177/002215549804600314.
17
18 534 [19] Hood BL, Darfler MM, Guiel TG, Furusato B, Lucas DA, Ringeisen BR, et al. Proteomic analysis of
19 535 formalin-fixed prostate cancer tissue. *Mol Cell Proteomics* 2005;4:1741–1753.
20 536 doi:10.1074/mcp.M500102-MCP200.
21
22 537 [20] Pallua JD, Schaefer G, Seifarth C, Becker M, Meding S, Rauser S, et al. MALDI-MS tissue imaging
23 538 identification of biliverdin reductase B overexpression in prostate cancer. *J Proteomics* 2013;91:500–
24 539 514. doi:10.1016/j.jprot.2013.08.003.
25
26 540 [21] Davalieva K, Kiprijanovska S, Polenakovic M. Assessment of the 2-d gel-based proteomics application of
27 541 clinically archived formalin-fixed paraffin embedded tissues. *Protein J* 2014;33:135–142.
28 542 doi:10.1007/s10930-014-9545-2.
29
30 543 [22] Iglesias-Gato D, Wikström P, Tyanova S, Lavalley C, Thysell E, Carlsson J, et al. The proteome of primary
31 544 prostate cancer. *Eur Urol* 2016;69:942–952. doi:10.1016/j.eururo.2015.10.053.
32
33 545 [23] Dunne JC, Lamb DS, Delahunt B, Murray J, Bethwaite P, Ferguson P, et al. Proteins from formalin-fixed
34 546 paraffin-embedded prostate cancer sections that predict the risk of metastatic disease. *Clin Proteomics*
35 547 2015;12:24. doi:10.1186/s12014-015-9096-3.
36
37 548 [24] Makridakis M, Vlahou A. GeLC-MS: A Sample Preparation Method for Proteomics Analysis of Minimal
38 549 Amount of Tissue. *Methods Mol Biol* 2018;1788:165–175. doi:10.1007/7651_2017_76.
39
40 550 [25] Mokou M, Klein J, Makridakis M, Bitsika V, Bascands J-L, Saulnier-Blache JS, et al. Proteomics based
41 551 identification of KDM5 histone demethylases associated with cardiovascular disease. *EBioMedicine*
42 552 2019;41:91–104. doi:10.1016/j.ebiom.2019.02.040.
43
44 553 [26] Schanstra JP, Luong TTD, Makridakis M, Van Linthout S, Lygirou V, Latosinska A, et al. Systems biology
45 554 identifies cytosolic PLA2 as a target in vascular calcification treatment. *JCI Insight* 2019.
46
47 555 [27] Korshak OV, Sushilova EN, Voskresenskii MA, Grozov RV, Komyakov BK, Zarytskey AY, et al. [Basal-
48 556 luminal epithelial cell differentiation in prostate cancer is associated with epithelial-mesenchymal
49 557 transition and epithelium migration in the mesenchyme]. *Urologiia* 2016:85–91.
50
51
52
53
54
55
56
57
58
59
60

- [28] Amaro A, Esposito AI, Gallina A, Nees M, Angelini G, Albin A, et al. Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel. *Cancer Metastasis Rev* 2014;33:657–671. doi:10.1007/s10555-013-9470-4.
- [29] Altintas DM, Allioli N, Decaussin M, de Bernard S, Ruffion A, Samarut J, et al. Differentially expressed androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate cancer. *PLoS One* 2013;8:e66278. doi:10.1371/journal.pone.0066278.
- [30] Valcarcel-Jimenez L, Macchia A, Martín-Martín N, Cortazar AR, Schaub-Clerigué A, Pujana-Vaquerizo M, et al. Integrative analysis of transcriptomics and clinical data uncovers the tumor-suppressive activity of MITF in prostate cancer. *Cell Death Dis* 2018;9:1041. doi:10.1038/s41419-018-1096-6.
- [31] Burch TC, Watson MT, Nyalwidhe JO. Variable metastatic potentials correlate with differential plectin and vimentin expression in syngeneic androgen independent prostate cancer cells. *PLoS One* 2013;8:e65005. doi:10.1371/journal.pone.0065005.
- [32] Hong SK, Ko DW, Park J, Kim IS, Doo SH, Yoon CY, et al. Alteration of Antithrombin III and D-dimer Levels in Clinically Localized Prostate Cancer. *Korean J Urol* 2010;51:25–29. doi:10.4111/kju.2010.51.1.25.
- [33] Wang Y, Guo W, Xu H, Zhu X, Yu T, Jiang Z, et al. An extensive study of the mechanism of prostate cancer metastasis. *Neoplasma* 2018;65:253–261. doi:10.4149/neo_2018_161217N648.
- [34] Elix C, Pal SK, Jones JO. The role of peroxisome proliferator-activated receptor gamma in prostate cancer. *Asian J Androl* 2018;20:238–243. doi:10.4103/aja.aja_15_17.
- [35] Chng KR, Chang CW, Tan SK, Yang C, Hong SZ, Sng NYW, et al. A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. *EMBO J* 2012;31:2810–2823. doi:10.1038/emboj.2012.112.
- [36] Geisler C, Gaisa NT, Pfister D, Fuessel S, Kristiansen G, Braunschweig T, et al. Identification and validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and MS. *Biomed Res Int* 2015;2015:454256. doi:10.1155/2015/454256.
- [37] Suhovskih AV, Mostovich LA, Kunin IS, Boboev MM, Nepomnyashchikh GI, Aidagulova SV, et al. Proteoglycan expression in normal human prostate tissue and prostate cancer. *ISRN Oncol* 2013;2013:680136. doi:10.1155/2013/680136.
- [38] Tyutyunnykova A, Teleguev G, Dubrovskaya A. The controversial role of phospholipase C epsilon (PLCε) in cancer development and progression. *J Cancer* 2017;8:716–729. doi:10.7150/jca.17779.
- [39] Shapiro E, Huang H, Ruoff R, Lee P, Tanese N, Logan SK. The heterochromatin protein 1 family is regulated in prostate development and cancer. *J Urol* 2008;179:2435–2439. doi:10.1016/j.juro.2008.01.091.
- [40] Basu A, Banerjee H, Rojas H, Martinez SR, Roy S, Jia Z, et al. Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. *Prostate* 2011;71:755–765. doi:10.1002/pros.21292.

1
2
3 593 [41] Tiedemann K, Sadvakassova G, Mikolajewicz N, Juhas M, Sabirova Z, Tabariès S, et al. Exosomal Release
4 594 of L-Plastin by Breast Cancer Cells Facilitates Metastatic Bone Osteolysis. *Transl Oncol* 2019;12:462–474.
5 595 doi:10.1016/j.tranon.2018.11.014.
6
7 596 [42] Rose A, Xu Y, Chen Z, Fan Z, Stamey TA, McNeal JE, et al. Comparative gene and protein expression in
8 597 primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer. *Cancer Lett*
9 598 2005;227:213–222. doi:10.1016/j.canlet.2005.01.037.
10
11 599 [43] van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA. Expression of basal cell
12 600 keratins in human prostate cancer metastases and cell lines. *J Pathol* 2001;195:563–570.
13 601 doi:10.1002/path.993.
14
15 602 [44] Shih JC. Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
16 603 *J Neural Transm* 2018;125:1553–1566. doi:10.1007/s00702-018-1927-8.
17
18 604 [45] Feichtinger RG, Schäfer G, Seifarth C, Mayr JA, Kofler B, Klocker H. Reduced Levels of ATP Synthase
19 605 Subunit ATP5F1A Correlate with Earlier-Onset Prostate Cancer. *Oxid Med Cell Longev*
20 606 2018;2018:1347174. doi:10.1155/2018/1347174.
21
22 607 [46] Orr B, Riddick ACP, Stewart GD, Anderson RA, Franco OE, Hayward SW, et al. Identification of stromally
23 608 expressed molecules in the prostate by tag-profiling of cancer-associated fibroblasts, normal fibroblasts
24 609 and fetal prostate. *Oncogene* 2012;31:1130–1142. doi:10.1038/onc.2011.312.
25
26 610 [47] Zhang X, Hu L, Du M, Wei X, Zhang J, Hui Y, et al. Eukaryotic elongation factor 2 (eef2) is a potential
27 611 biomarker of prostate cancer. *Pathol Oncol Res* 2018;24:885–890. doi:10.1007/s12253-017-0302-7.
28
29 612 [48] Planchon SM, Pink JJ, Tagliarino C, Bornmann WG, Varnes ME, Boothman DA. beta-Lapachone-induced
30 613 apoptosis in human prostate cancer cells: involvement of NQO1/xip3. *Exp Cell Res* 2001;267:95–106.
31 614 doi:10.1006/excr.2001.5234.
32
33 615 [49] Kumi-Diaka J, Saddler-Shawnette S, Aller A, Brown J. Potential mechanism of phytochemical-induced
34 616 apoptosis in human prostate adenocarcinoma cells: Therapeutic synergy in genistein and beta-
35 617 lapachone combination treatment. *Cancer Cell Int* 2004;4:5. doi:10.1186/1475-2867-4-5.
36
37 618 [50] Heger Z, Michalek P, Guran R, Cernei N, Duskova K, Vesely S, et al. Differences in urinary proteins
38 619 related to surgical ' ' margin status after radical prostatectomy. *Oncol Rep* 2015;34:3247–3255.
39 620 doi:10.3892/or.2015.4322.
40
41 621 [51] Feng J, Huang C, Diao X, Fan M, Wang P, Xiao Y, et al. Screening biomarkers of prostate cancer by
42 622 integrating microRNA and mRNA microarrays. *Genet Test Mol Biomarkers* 2013;17:807–813.
43 623 doi:10.1089/gtmb.2013.0226.
44
45 624 [52] Miller D, Ingersoll M, Lin M-F. ErbB-2 signaling in advanced prostate cancer progression and potential
46 625 therapy. *Endocr Relat Cancer* 2019;26:R195–R209. doi:10.1530/ERC-19-0009.
47
48 626 [53] Srihari S, Kwong R, Tran K, Simpson R, Tattam P, Smith E. Metabolic deregulation in prostate cancer.
49 627 *Mol Omics* 2018;14:320–329. doi:10.1039/c8mo00170g.
50
51
52
53
54
55
56
57
58
59
60

- [54] Kelly RS, Sinnott JA, Rider JR, Ebot EM, Gerke T, Bowden M, et al. The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. *Cancer Metab* 2016;4:22. doi:10.1186/s40170-016-0161-9.
- [55] Ramamurthy VP, Ramalingam S, Kwegyir-Afful AK, Hussain A, Njar VCO. Targeting of protein translation as a new treatment paradigm for prostate cancer. *Curr Opin Oncol* 2017. doi:10.1097/CCO.0000000000000367.
- [56] Carvalho-Silva D, Pierleoni A, Pignatelli M, Ong C, Fumis L, Karamanis N, et al. Open Targets Platform: new developments and updates two years on. *Nucleic Acids Res* 2019;47:D1056–D1065. doi:10.1093/nar/gky1133.
- [57] Chu W-S, Liang Q, Liu J, Wei MQ, Winters M, Liotta L, et al. A nondestructive molecule extraction method allowing morphological and molecular analyses using a single tissue section. *Lab Invest* 2005;85:1416–1428. doi:10.1038/labinvest.3700337.
- [58] Hwang SI, Thumar J, Lundgren DH, Rezaul K, Mayya V, Wu L, et al. Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues. *Oncogene* 2007;26:65–76. doi:10.1038/sj.onc.1209755.
- [59] Chung J-Y, Lee S-J, Kris Y, Braunschweig T, Traicoff JL, Hewitt SM. A well-based reverse-phase protein array applicable to extracts from formalin-fixed paraffin-embedded tissue. *Proteomics Clin Appl* 2008;2:1539–1547. doi:10.1002/prca.200800005.
- [60] Shi S-R, Liu C, Balgley BM, Lee C, Taylor CR. Protein extraction from formalin-fixed, paraffin-embedded tissue sections: quality evaluation by mass spectrometry. *J Histochem Cytochem* 2006;54:739–743. doi:10.1369/jhc.5B6851.2006.
- [61] Ha GH, Lee SU, Kang DG, Ha N-Y, Kim SH, Kim J, et al. Proteome analysis of human stomach tissue: separation of soluble proteins by two-dimensional polyacrylamide gel electrophoresis and identification by mass spectrometry. *Electrophoresis* 2002;23:2513–2524. doi:10.1002/1522-2683(200208)23:15<2513::AID-ELPS2513>3.0.CO;2-W.
- [62] Yamashita S. Heat-induced antigen retrieval: mechanisms and application to histochemistry. *Prog Histochem Cytochem* 2007;41:141–200. doi:10.1016/j.proghi.2006.09.001.
- [63] Rait VK, Xu L, O’Leary TJ, Mason JT. Modeling formalin fixation and antigen retrieval with bovine pancreatic RNase A II. Interrelationship of cross-linking, immunoreactivity, and heat treatment. *Lab Invest* 2004;84:300–306. doi:10.1038/labinvest.3700041.
- [64] Addis MF, Tanca A, Pagnozzi D, Crobu S, Fanciulli G, Cossu-Rocca P, et al. Generation of high-quality protein extracts from formalin-fixed, paraffin-embedded tissues. *Proteomics* 2009;9:3815–3823. doi:10.1002/pmic.200800971.
- [65] Sprung RW, Brock JWC, Tanksley JP, Li M, Washington MK, Slebos RJC, et al. Equivalence of protein inventories obtained from formalin-fixed paraffin-embedded and frozen tissue in multidimensional liquid chromatography-tandem mass spectrometry shotgun proteomic analysis. *Mol Cell Proteomics* 2009;8:1988–1998. doi:10.1074/mcp.M800518-MCP200.

1
2
3 665 [66] Scicchitano MS, Dalmas DA, Boyce RW, Thomas HC, Frazier KS. Protein extraction of formalin-fixed,
4 666 paraffin-embedded tissue enables robust proteomic profiles by mass spectrometry. *J Histochem*
5 667 *Cytochem* 2009;57:849–860. doi:10.1369/jhc.2009.953497.
6
7 668 [67] Guo T, Wang W, Rudnick PA, Song T, Li J, Zhuang Z, et al. Proteome analysis of microdissected formalin-
8 669 fixed and paraffin-embedded tissue specimens. *J Histochem Cytochem* 2007;55:763–772.
9 670 doi:10.1369/jhc.7A7177.2007.
10
11 671 [68] Nirmalan NJ, Harnden P, Selby PJ, Banks RE. Development and validation of a novel protein extraction
12 672 methodology for quantitation of protein expression in formalin-fixed paraffin-embedded tissues using
13 673 western blotting. *J Pathol* 2009;217:497–506. doi:10.1002/path.2504.
14
15 674 [69] Gräntzdörffer I, Yumlu S, Gioeva Z, von Wasielewski R, Ebert MPA, Röcken C. Comparison of different
16 675 tissue sampling methods for protein extraction from formalin-fixed and paraffin-embedded tissue
17 676 specimens. *Exp Mol Pathol* 2010;88:190–196. doi:10.1016/j.yexmp.2009.09.009.
18
19 677 [70] Hood BL, Conrads TP, Veenstra TD. Mass spectrometric analysis of formalin-fixed paraffin-embedded
20 678 tissue: unlocking the proteome within. *Proteomics* 2006;6:4106–4114. doi:10.1002/pmic.200600016.
21
22 679 [71] Becker KF, Schott C, Hipp S, Metzger V, Porschewski P, Beck R, et al. Quantitative protein analysis from
23 680 formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis.
24 681 *J Pathol* 2007;211:370–378. doi:10.1002/path.2107.
25
26 682 [72] Palmer-Toy DE, Krastins B, Sarracino DA, Nadol JB, Merchant SN. Efficient method for the proteomic
27 683 analysis of fixed and embedded tissues. *J Proteome Res* 2005;4:2404–2411. doi:10.1021/pr050208p.
28
29 684 [73] Wang D, Eraslan B, Wieland T, Hallström B, Hopf T, Zolg DP, et al. A deep proteome and transcriptome
30 685 abundance atlas of 29 healthy human tissues. *Mol Syst Biol* 2019;15:e8503.
31 686 doi:10.15252/msb.20188503.
32
33 687 [74] Yocum AK, Khan AP, Zhao R, Chinnaiyan AM. Development of selected reaction monitoring-MS
34 688 methodology to measure peptide biomarkers in prostate cancer. *Proteomics* 2010;10:3506–3514.
35 689 doi:10.1002/pmic.201000023.
36
37 690 [75] Tanase CP, Codrici E, Popescu ID, Mihai S, Enciu A-M, Necula LG, et al. Prostate cancer proteomics:
38 691 Current trends and future perspectives for biomarker discovery. *Oncotarget* 2017;8:18497–18512.
39 692 doi:10.18632/oncotarget.14501.
40
41 693 [76] Kolonin M, Sergeeva A, Staquicini D, Molldrem JJ, Pasqualini R, Arap W. Neutrophil-Secreted Proteinase
42 694 3 Mediates Metastasis of Prostate Cancer Cells Expressing RAGE to the Bone Marrow. *Blood*
43 695 2016;128:1025–1025. doi:10.1182/blood.V128.22.1025.1025.
44
45 696 [77] Engers R, Ziegler S, Mueller M, Walter A, Willers R, Gabbert HE. Prognostic relevance of increased Rac
46 697 GTPase expression in prostate carcinomas. *Endocr Relat Cancer* 2007;14:245–256. doi:10.1677/ERC-06-
47 698 0036.
48
49 699 [78] Rodríguez-Berriguete G, Fraile B, Martínez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M. MAP
50 700 Kinases and Prostate Cancer. *J Signal Transduct* 2012;2012:169170. doi:10.1155/2012/169170.
51
52
53
54
55
56
57
58
59
60

- 701 [79] Walker C, Mojares E, Del Río Hernández A. Role of extracellular matrix in development and cancer
702 progression. *Int J Mol Sci* 2018;19. doi:10.3390/ijms19103028.
- 703 [80] Antonopoulou E, Lodomery M. Targeting splicing in prostate cancer. *Int J Mol Sci* 2018;19.
704 doi:10.3390/ijms19051287.
- 705 [81] Culig Z, Santer FR. Androgen receptor signaling in prostate cancer. *Cancer Metastasis Rev* 2014;33:413–
706 427. doi:10.1007/s10555-013-9474-0.
- 707 [82] Dai C, Heemers H, Sharifi N. Androgen signaling in prostate cancer. *Cold Spring Harb Perspect Med*
708 2017;7. doi:10.1101/cshperspect.a030452.
- 709 [83] Belinky F, Nativ N, Stelzer G, Zimmerman S, Iny Stein T, Safran M, et al. PathCards: multi-source
710 consolidation of human biological pathways. *Database (Oxford)* 2015;2015.
711 doi:10.1093/database/bav006.
- 712 [84] Androgen receptor signaling pathway. PathCards Pathway Unification Database n.d.
713 https://pathcards.genecards.org/Card/androgen_receptor_signaling_pathway?queryString=ANDROGEN
714 (accessed October 14, 2019).
- 715 [85] Webber JP, Spary LK, Mason MD, Tabi Z, Brewis IA, Clayton A. Prostate stromal cell proteomics analysis
716 discriminates normal from tumour reactive stromal phenotypes. *Oncotarget* 2016;7:20124–20139.
717 doi:10.18632/oncotarget.7716.
- 718

203x101mm (300 x 300 DPI)